US2009117134A1PendingUtilityA1

Truncated EGF Receptor

58
Assignee: COMMW SCIENT IND RES ORGPriority: Jun 28, 2000Filed: Oct 20, 2008Published: May 7, 2009
Est. expiryJun 28, 2020(expired)· nominal 20-yr term from priority
Inventors:Colin Wesley WardNeil Moreton MckernGeorge LovreczRobert JorissenThomas Peter John GarrettThomas EllemanAnthony BurgessTimothy AdamsTeresa DomagalaEdouard Collins Nice
A61P 43/00A61P 35/00A61P 17/06C07K 14/71
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to truncated EGF receptor molecules that exhibit increased binding affinities for EGFR ligands such as EGF and TGF1. The present invention also relates to methods of screening for EGF receptor ligands and methods of treatment which involve the use of these molecules.

Claims

exact text as granted — not AI-modified
1 . An isolated or purified truncated ErbB3 epidermal growth factor receptor (EGFR) ectodomain comprising at least residues 1 to 491 of ErbB3 (SEQ ID NO:3), the truncated EGFR ectodomain lacking at least the third to seventh modules of the CR2 domain such that the truncated EGFR ectodomain has an increased binding affinity for at least one EGFR ligand when compared to the full length EGFR ectodomain. 
     
     
         2 . The truncated EGFR ectodomain of  claim 1  wherein the truncated EGFR ectodomain lacks at least the second to seventh modules of the CR2 domain. 
     
     
         3 . The truncated EGFR ectodomain of  claim 1  wherein the truncated EGFR ectodomain further lacks a portion of the first module of the CR2 domain. 
     
     
         4 . The truncated EGFR ectodomain of  claim 1  wherein the truncated EGFR ectodomain lacks residues 513-624 of ErbB3 (SEQ ID NO:3). 
     
     
         5 . The truncated EGFR ectodomain of  claim 4  wherein the truncated EGFR ectodomain lacks residues 501-624 of ErbB3 (SEQ ID NO:3). 
     
     
         6 . The truncated EGFR ectodomain of  claim 1  wherein the truncated EGFR ectodomain comprises residues 1-500 or residues 1-512 of ErbB3 (SEQ ID NO:3). 
     
     
         7 . The truncated EGFR ectodomain of  claim 1  wherein the truncated EGFR ectodomain consists of residues 1-500 or residues 1-512 of ErbB3 (SEQ ID NO:3). 
     
     
         8 . A chimeric or fusion construct comprising a truncated EGFR ectodomain of  claim 1 . 
     
     
         9 . The chimeric or fusion construct of  claim 8  wherein the truncated EGFR ectodomain is conjugated to an immunoglobulin constant domain. 
     
     
         10 . The chimeric or fusion construct of  claim 9  wherein the construct comprises residues 1-500 of ErbB3 (SEQ ID NO:3) fused to an immunoglobulin constant domain. 
     
     
         11 . A dimer of the chimeric or fusion protein of  claim 9 . 
     
     
         12 . A homodimer of the chimeric or fusion protein of  claim 9 . 
     
     
         13 . A pharmaceutical composition comprising the truncated EGFR ectodomain of  claim 1  and a pharmaceutically acceptable carrier or diluent. 
     
     
         14 . A pharmaceutical composition comprising the chimeric or fusion construct of  claim 9  and a pharmaceutically acceptable carrier or diluent. 
     
     
         15 . The truncated EGFR ectodomain of  claim 1  wherein the truncated ErbB3 EGFR ectodomain has an affinity for HRGβ such that the IC 50  is 0.49 nM.

Join the waitlist — get patent alerts

Track US2009117134A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.